Combined proteomic and transcriptomic approaches reveal externalized keratin 8 as a potential therapeutic target involved in invasiveness of head and neck cancers.


Journal

Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 25 06 2020
accepted: 29 06 2020
pubmed: 4 10 2020
medline: 4 10 2020
entrez: 3 10 2020
Statut: ppublish

Résumé

Keratin 8 (K8) expressed at the surface of cancer cells, referred as externalized K8 (eK8), has been observed in a variety of carcinoma cell lines. K8 has been previously reported to be expressed in poorly differentiated head and neck squamous cell carcinoma (HNSCC); however, its role during the invasive phase of upper aerodigestive tract tumorigenesis is unknown. Cohorts of HNSCC tumors for protein and mRNA expression and panel of cell lines were used for investigation. K8 was found to be externalized in a majority of HNSCC cell lines. Among the two main K8 protein isoforms only the 54 kDa was found to be present at the plasma membrane of HNSCC cells. The plasminogen-induced invasion of HNSCC cells was inhibited by the anti-eK8 D-A10 antagonist monoclonal antibody. Overexpression of K8 mRNA and protein were both correlated with tumor aggressive features and poor outcome. The effect of eK8 neutralization on invasion, its presence exclusively in cancer cells and the association of K8 expression with aggressive features and poor clinical outcome in HNSCC unravel eK8 as key player in invasion and a promising therapeutic target in HNSCC.

Identifiants

pubmed: 33010552
pii: S1936-5233(20)30370-3
doi: 10.1016/j.tranon.2020.100878
pmc: PMC7530345
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100878

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Arch Surg. 1990 Jan;125(1):107-13
pubmed: 1688490
J Comp Neurol. 2003 Mar 3;457(2):111-22
pubmed: 12541313
Gene. 1990 Feb 14;86(2):241-9
pubmed: 1691124
J Biol Chem. 2002 Mar 29;277(13):10775-82
pubmed: 11788583
Nucleic Acids Res. 2003 Jul 1;31(13):3784-8
pubmed: 12824418
Blood. 2009 May 28;113(22):5371-2
pubmed: 19478049
J Cell Sci. 1995 Mar;108 ( Pt 3):1071-82
pubmed: 7542667
PLoS One. 2011;6(11):e27767
pubmed: 22114688
Lung Cancer. 2002 Oct;38(1):31-8
pubmed: 12367790
Nucleic Acids Res. 2010 Jan;38(Database issue):D492-6
pubmed: 19854944
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Genomics Proteomics. 2011 Mar-Apr;8(2):49-63
pubmed: 21471515
Biochem Biophys Res Commun. 2006 Apr 28;343(1):252-9
pubmed: 16540085
BMC Cancer. 2008 Sep 22;8:267
pubmed: 18803884
Oral Oncol. 2018 Nov;86:301-306
pubmed: 30409316
Eur J Cancer. 1998 Dec;34(14 Spec No):2154-61
pubmed: 10070281
Head Neck. 2016 Feb;38(2):208-15
pubmed: 25225171
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Nature. 1970 Aug 15;227(5259):680-5
pubmed: 5432063
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
Int J Cancer. 2009 Apr 15;124(8):1802-10
pubmed: 19115206
Cancer Epidemiol. 2019 Dec;63:101615
pubmed: 31586822
Mayo Clin Proc. 2008 Apr;83(4):489-501
pubmed: 18380996
Clin Cancer Res. 2011 Dec 1;17(23):7248-64
pubmed: 21868764
Oral Oncol. 2020 Jun;105:104662
pubmed: 32278110
J Cell Biol. 2011 Sep 5;194(5):669-78
pubmed: 21893596
Oral Oncol. 2010 Oct;46(10):720-6
pubmed: 20728401
J Biol Chem. 1996 Oct 11;271(41):25684-91
pubmed: 8810346
Eur Arch Otorhinolaryngol. 1997;254(8):376-83
pubmed: 9332893
Cancers (Basel). 2018 Nov 16;10(11):
pubmed: 30453567
Biochem Biophys Res Commun. 2005 Mar 25;328(4):1154-62
pubmed: 15707998
Exp Hematol Oncol. 2013 Apr 17;2(1):12
pubmed: 23594883
PLoS One. 2012;7(6):e38561
pubmed: 22701666
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Anticancer Res. 2015 Jul;35(7):3953-60
pubmed: 26124342
BMC Cancer. 2006 Jan 13;6:10
pubmed: 16412231
J Anat. 1998 Aug;193 ( Pt 2):185-93
pubmed: 9827634

Auteurs

Marie Alexandra Albaret (MA)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France.

Arnaud Paré (A)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France; Department of Maxillofacial and Plastic surgery, CHRU of Tours, 37170 Chambray-lés-Tours, France; University of François Rabelais, School of Medicine, Tours F-37032, France.

Lucie Malet (L)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France.

Geneviève De Souza (G)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France.

Emilie Lavergne (E)

Biostatistics Unit, Centre Léon Bérard, 69373 Lyon, France.

Dominique Goga (D)

Department of Maxillofacial and Plastic surgery, CHRU of Tours, 37170 Chambray-lés-Tours, France; University of François Rabelais, School of Medicine, Tours F-37032, France.

Gonzague De Pinieux (G)

Department of Pathology, CHRU of Tours, 37170 Chambray-lés-Tours, France; University of François Rabelais, School of Medicine, Tours F-37032, France.

Claire Castellier (C)

Department of Pathology, CHRU of Tours, 37170 Chambray-lés-Tours, France; University of François Rabelais, School of Medicine, Tours F-37032, France.

Aurélie Swalduz (A)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France; Department of Medicine, Centre Léon Bérard, 69373 Lyon, France.

Vivian Robin (V)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France.

Vincent Lavergne (V)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France.

Hichem-Claude Mertani (HC)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France.

Isabelle Treilleux (I)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France; Department of Pathology, Centre Léon Bérard, 69373 Lyon, France.

Claudine Vermot-Desroches (C)

IDD BIOTECH, Bâtiment Accinov, 317 avenue Jean Jaurès, 69007, Lyon, France.

Jean-Jacques Diaz (JJ)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France. Electronic address: jean-jacques.diaz@lyon.unicancer.fr.

Pierre Saintigny (P)

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008 Lyon, France; Department of Translational Research and Innovation, Centre Léon Bérard, 69373 Lyon, France; Department of Medicine, Centre Léon Bérard, 69373 Lyon, France. Electronic address: pierre.saintigny@lyon.unicancer.fr.

Classifications MeSH